Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

Rafael Daltro De Oliveira, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Clemence Marcault, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Nathalie Parquet, MD, Emmanuel Raffoux, MD, William Vainchenker, Christine Chomienne, MD PhD, Bruno Cassinat, PharmD, PhD, Lina Benajiba, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141223

Published: 2020

Journal Articles

JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators

Marion Strullu, MD, Aurélie Caye-Eude, PharmD, PhD, Loïc Maillard, PhD, Chloé Arfeuille, MD, Elodie Lainey, PharmD, PhD, Florian Piques, MD, Odile Fenneteau, PharmD, Bruno Cassinat, PharmD, PhD, Fabien Guimiot, PhD, Jean-Hugues Dalle, MD PhD, André Baruchel, Christine Chomienne, MD PhD, Dominique Bonnet, PhD, Michele Souyri, PhD, Hélène Cavé, PharmD, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-136367

Published: 2020

Journal Articles

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Rose Ann Padua, PhD, Laure Sarda-Mantel, MD PhD, Mathieu Chiquet, BSc, Claire Kappel, BSc, Patricia Krief, PhD, Niclas Setterblad, PhD, Fortune Hontonnou, BSc, Benoit Hosten, PhD, Nicolas Vignal, BSc, Fabien Zassadowski, PhD, Bruno Cassinat, PharmD, PhD, Panhong Gou, BSc, Stephane Giraudier, MD PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2018) 132 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2018-99-114212

Published: 2018

Journal Articles

Potential of Plasmatic Biomarkers to Predict Acute Gvhd Severity: A Validation Study in a Prospective Cohort of 177 Patients

Marie Robin, MD PhD, Raphael Porcher, PhD, Laetitia Taurines, Bastien Oriano, Regis Peffault De Latour, MD PhD, Flore Sicre De Fontbrune, MD, David Michonneau, MD PhD, Nathalie Dhedin, MD, Christine Chomienne, MD PhD, Gérard Socié, MDPhD, Marie-Hélène Schlageter, PharmD

Blood (2017) 130 (Supplement 1): 4480.

https://doi.org/10.1182/blood.V130.Suppl_1.4480.4480

Published: 2017

Journal Articles

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Rose Ann Padua, PhD, Mathieu Chiquet, BSc, Qi Zhang, PhD MD, Claire Kappel, Patricia Krief, PhD, Niclas Setterblad, PhD, Dr Omidvar, BSc, MSc, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2017) 130 (Supplement 1): 2613.

https://doi.org/10.1182/blood.V130.Suppl_1.2613.2613

Published: 2017

Journal Articles

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Juliette Soret, MD, Bruno Cassinat, PharmD, PhD, Sylvie Chevret, MD PhD, Christine Dosquet, MD PhD, Stephane Giraudier, MD PhD, Emmanuelle Verger, PhD, Nabih Maslah, PhD, Nathalie Parquet, MD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 3106.

https://doi.org/10.1182/blood.V128.22.3106.3106

Published: 2016

Journal Articles

Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists

Blood (2016) 128 (22): 2555.

https://doi.org/10.1182/blood.V128.22.2555.2555

Published: 2016

Journal Articles

JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics

Anna Guadall, PhD, Elodie Lesteven, PharmD, PhD, Gil Letort, Sarah Awan Toor, Doriane Pognant, Megane Brusson, Emmanuelle Verger, PhD, Jerome Larghero, PharmD, PhD, Valerie Vanneaux, PharmD, PhD, Christine Chomienne, MD PhD, Wassim El Nemer, PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 4273.

https://doi.org/10.1182/blood.V128.22.4273.4273

Published: 2016

Journal Articles

Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms

Nadine Ajzenberg, MD PhD, Dorothee Faille, PharmD, PhD, Lamia Lamrani, PhD, Stéphane Loyau, Marie-Geneviève Huisse, MD PhD, Nicolas Dumontier, PharmD, Martine Jandrot-Perrus, MD PhD, Sawsaneh Alkhaier, Bruno Cassinat, PharmD, PhD, Christine Chomienne, MD PhD, Christine Dosquet, MD PhD

Blood (2016) 128 (22): 1941.

https://doi.org/10.1182/blood.V128.22.1941.1941

Published: 2016

Journal Articles

Metabolic Rewiring Drives Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia

Nithya Balasundaram, MSc, Saravanan Ganesan, MSc, Hamenth Kumar Palani, MSc, Ansu Abu Alex, MSc, Sachin David, MSc, Anu Korula, MD DM, Biju George, MD DM, Christine Chomienne, MD PhD, Poonkuzhali Balasubramanian, MSc PhD, Vikram Mathews, MD DM

Blood (2016) 128 (22): 3956.

https://doi.org/10.1182/blood.V128.22.3956.3956

Published: 2016

Journal Articles

Benzene-Induced Leukemogenesis: Irreversible Inhibition of PTPN2 and Subsequent STAT1 Signaling Alteration By the Hematotoxic Metabolite Benzoquinone

Romain Duval, Linh-Chi Bui, PhD, Cécile Mathieu, Emile Petit, Jean-Marie Dupret, PhD, Jan Cools, PhD, Fabien Guidez, PhD, Christine Chomienne, MD PhD, Fernando Rodrigues-Lima, PhD

Blood (2015) 126 (23): 3671.

https://doi.org/10.1182/blood.V126.23.3671.3671

Published: 2015

Journal Articles

Final Results of a Phase 1 Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Myelofibrosis ( FLT-MF-2009 Study)

Annalisa Andreoli, MD, Laetitia Vercellino, MD, Matthieu John Ouvrier, MD, Emmanuelle Barré, PharmD, Bruno Cassinat, PharmD, PhD, Virginie de Beco, PharmD, Pascal Merlet, MD PhD, Christine Dosquet, MD PhD, Christine Chomienne, MD PhD, Sylvie Chevret, MD PhD, Marie-Elisabeth Toubert, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 3195.

https://doi.org/10.1182/blood.V124.21.3195.3195

Published: 2014

Journal Articles

Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ?

Nadine Ajzenberg, MD PhD, Dorothee Faille, PharmD, PhD, Marie-Genevieve Huisse, MD PhD, Anh Hong Cung, Pharm D, Lamia Lamrani, Nicolas Dumontier, Pharm D, Martine Jandrot-Perrus, MD PhD, Bruno Cassinat, PharmD, PhD, Christine Chomienne, MD PhD, Christine Dosquet, MD PhD

Blood (2014) 124 (21): 3200.

https://doi.org/10.1182/blood.V124.21.3200.3200

Published: 2014

Journal Articles

Identification of PLZF-Dmrs in Hematopoiesis Highlight a Novel Role of PLZF As a Guardian of Hematopoietic Genome Integrity

Fabien Guidez, PhD, Laetitia Durand, Technician, Valerie Vidal, William Puszyk, PhD, David Grimwade, Ellen Solomon, Christine Chomienne, MD PhD

Blood (2014) 124 (21): 2904.

https://doi.org/10.1182/blood.V124.21.2904.2904

Published: 2014

Journal Articles

BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Valerie Vidal, Clemence Ginet, Jean Michel Karsenti, MD, Frederic Luciano, PhD, Lauris Gastaud, MD, Georges Garnier, MD, Thorsten Braun, MD, Pierre Hirsch, MD, Emmanuel Raffoux, MD, Anne Marie Nloga, Herve Dombret, MD, Pierre-Simon Rohrlich, Lionel Ades, MD PhD, Christine Chomienne, MD PhD, Pierre Fenaux, MD PhD, Patrick Auberger, PhD, Guillaume Robert, PhD, Thomas Cluzeau, MD PhD

Blood (2014) 124 (21): 3261.

https://doi.org/10.1182/blood.V124.21.3261.3261

Published: 2014

Journal Articles

Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling

Blood (2014) 124 (21): 3249.

https://doi.org/10.1182/blood.V124.21.3249.3249

Published: 2014

Journal Articles

Impact of the JAK2V617F Mutation on the Hemato-Endothelial Differentiation in an Induced Pluripotent Stem Cells (iPSC) Model

Elodie Lesteven, PharmD, PhD, Doriane Pognant, Valerie Vanneaux, PharmD, PhD, Jérome Larghero, PharmD, PhD, Olivier Feraud, Annelise Bennaceur-Griscelli, MD PhD, Emmanuelle Verger, PhD, Annalisa Andreoli, MD, Christine Chomienne, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 4570.

https://doi.org/10.1182/blood.V124.21.4570.4570

Published: 2014

Journal Articles

Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

Emmanuelle Verger, PhD, Bruno Cassinat, PharmD, PhD, Christine Dosquet, MD PhD, Marie-Helene Schlageter, Valérie Ugo, MD PhD, Jean-Christophe Ianotto, MD, Mohamed A. Yassin, MBBS ,MSc,CABM,FACP, Nader Dewik, PhD, Serge Carillo, PhD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 407.

https://doi.org/10.1182/blood.V124.21.407.407

Published: 2014

Journal Articles

Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia

Saravanan Ganesan, MSc, Ansu Abu Alex, MSc, Ezhilarasi Chendamarai, PhD, Nithya Balasundaram, MSc, Hamenth Kumar Palani, MSc, Sachin David, MSc, Jayandharan G Rao, PhD, Aby Abraham, MD, Auro Viswabandya, MD, Biju George, MD, Alok Srivastava, MD, Poonkuzhali Balasubramanian, PhD, Rose Ann Padua, PhD, Christine Chomienne, MD PhD, Vikram Mathews, MD

Blood (2014) 124 (21): 3741.

https://doi.org/10.1182/blood.V124.21.3741.3741

Published: 2014

Journal Articles

NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance

Ansu Abu Alex, MSc, Hamenth Kumar P, MSc, Saravanan Ganesan, MSc, Nithya Balasundaram, MSc, Kavitha M Lakshmi, MSc, Biju George, MD, Aby Abraham, MD, Auro Viswabandya, MD, Alok Srivastava, MD, Rose Ann Padua, PhD, Christine Chomienne, MD, PhD, Poonkuzhali Balasubramanian, Ph.D, Vikram Mathews, MD

Blood (2013) 122 (21): 1455.

https://doi.org/10.1182/blood.V122.21.1455.1455

Published: 2013

NARROW

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Potential of Plasmatic Biomarkers to Predict Acute Gvhd Severity: A Validation Study in a Prospective Cohort of 177 Patients

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists

JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics

Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms

Metabolic Rewiring Drives Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia

Benzene-Induced Leukemogenesis: Irreversible Inhibition of PTPN2 and Subsequent STAT1 Signaling Alteration By the Hematotoxic Metabolite Benzoquinone

Final Results of a Phase 1 Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Myelofibrosis ( FLT-MF-2009 Study)

Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ?

Identification of PLZF-Dmrs in Hematopoiesis Highlight a Novel Role of PLZF As a Guardian of Hematopoietic Genome Integrity

BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling

Impact of the JAK2V617F Mutation on the Hemato-Endothelial Differentiation in an Induced Pluripotent Stem Cells (iPSC) Model

Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia

NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only